Preliminary experience with sunitinib in VHL is also promising; six months’ treatment in a patient with multiple renal and pancreatic tumors and a malignant pheochromocytoma was associated with normalization of performance status, pain resolution, and reductions in tumor size [10], another patient with VHL-related mRCC achieved complete remission of these tumors after sunitinib therapy [11], and partial response/stable disease was evident in a patient with pancreatic neuroendocrine and RCC tumors who received sunitinib for nearly 5 years [12]. This evidence concerns the gene VHL and renal cell carcinoma.